Sands Capital

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

PgEdge specializes in providing distributed PostgreSQL solutions that enhance network edge performance, minimize data latency, and ensure ultra-high availability for critical applications. The company's technology features multi-master replication capabilities, allowing for active-active operations across various geographic regions. This setup enables developers to easily build and deploy highly distributed database applications within a fully managed cloud service. By integrating multi-active, multi-master, multi-region, and multi-cloud functionalities, PgEdge supports users in creating robust database environments that can efficiently operate on a global scale.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.